跳至主要内容
临床试验/NCT00056472
NCT00056472已完成3 期

Effectiveness of Selective Serotonin Reuptake Inhibitors Combined With Antipsychotic Medication for the Treatment of Psychotic Depression

Weill Medical College of Cornell University4 个研究点 分布在 2 个国家目标入组 259 人开始时间: 2003年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
259
试验地点
4
主要终点
Remission of Depression Hamilton Depression Scale (Ham-D) and Psychosis Schedule for Affective Disorders in Schizophrenia - Delusional Item (SADS) During the Course of the Trial

研究概览

简要总结

This study will determine the effectiveness of combining selective serotonin reuptake inhibitors (SSRIs) with antipsychotic medications in the treatment of psychotic depression.

详细描述

Approximately 25% of people who are admitted to hospitals for depression suffer from psychotic depression. People with psychotic depression experience hallucinations,and, more commonly delusions, in addition to major depression. Psychotic experiences may be either congruent with the theme of depression or incongruent, without an apparent relationship to feeling depressed. This study will determine the effectiveness of combining a selective serotonin reuptake inhibitor (SSRI) with antipsychotic medication in the treatment of psychotic depression accompanied by at least one identifiable delusion. The study will also evaluate the difference in treatment response of young adults versus geriatric patients.

This double-blind study will last a total of 12 weeks. Participants will be randomly assigned to receive either olanzapine, an atypical antipsychotic drug, combined with sertraline, an SSRI, or olanzapine alone. Following baseline assessments, study visits will occur weekly until Week 6, and then bi-weekly until Week 12. Participants who do not respond to either treatment may leave the study at any time. Participants who achieve either partial or full response may participate in an additional 20-week study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Major depressive disorder, single or recurrent, with psychotic features

排除标准

  • History of substance abuse or dependence within the 3 months prior to enrollment
  • Acute or unstable medical illness
  • Diagnosis of schizophrenia or other psychotic disorders
  • Intolerance to SSRIs or olanzapine

研究组 & 干预措施

olanzapine/sertraline combination

Active Comparator

sertraline plus olanzapine

干预措施: Olanzapine (Drug)

olanzapine/sertraline combination

Active Comparator

sertraline plus olanzapine

干预措施: Sertraline (Drug)

olanzapine plus placebo

Placebo Comparator

olanzapine (5 - 20mg/day) plus placebo

干预措施: Olanzapine (Drug)

olanzapine plus placebo

Placebo Comparator

olanzapine (5 - 20mg/day) plus placebo

干预措施: placebo (Other)

结局指标

主要结局

Remission of Depression Hamilton Depression Scale (Ham-D) and Psychosis Schedule for Affective Disorders in Schizophrenia - Delusional Item (SADS) During the Course of the Trial

时间窗: Weeks 1 to 12

Remission was defined as scores on Ham-D of less than 10 at two consecutive assessments and the absence of delusions (measured as SADS delusional item scores of 1) at the second assessment of the two-assessment remission of depression interval. Scores on Ham-D range from 0 to 52 with higher scores indicating more severe depression. Scores on SADS range from 1 to 7 with higher scores indicating the delusions(s) more adversely effect the subject's behavior.

次要结局

  • Scores on CGI-S Compared to Baseline Over the Course of the Trial(Weeks 1 to 12)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验